Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alemtuzumab long-term immunologic effect
Stefania De Mercanti, Simona Rolla, Angele Cucci, et al.
Neurology Neuroimmunology & Neuroinflammation (2016) Vol. 3, Iss. 1
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

The role of TH17 cells in multiple sclerosis: Therapeutic implications
Tobias Moser, Katja Akgün, Undine Proschmann, et al.
Autoimmunity Reviews (2020) Vol. 19, Iss. 10, pp. 102647-102647
Closed Access | Times Cited: 212
Resolution of inflammation during multiple sclerosis
Florian Ruiz, Solenne Vigne, Caroline Pot
Seminars in Immunopathology (2019) Vol. 41, Iss. 6, pp. 711-726
Open Access | Times Cited: 108
Immune reconstitution therapies: concepts for durable remission in multiple sclerosis
Jan D. Lünemann, Tobias Ruck, Paolo A. Muraro, et al.
Nature Reviews Neurology (2019) Vol. 16, Iss. 1, pp. 56-62
Closed Access | Times Cited: 91
Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018
Sneha Suresh, Julia Upton, Michael Green, et al.
Pediatric Transplantation (2019) Vol. 23, Iss. 7
Closed Access | Times Cited: 83
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
Tobias Ruck, Sumanta Barman, Andreas Schulte‐Mecklenbeck, et al.
Brain (2022) Vol. 145, Iss. 5, pp. 1711-1725
Open Access | Times Cited: 41
Diversity and function of regulatory T cells in health and autoimmune diseases
Yi Lu, Xiao‐Yong Man
Journal of Autoimmunity (2025) Vol. 151, pp. 103357-103357
Closed Access | Times Cited: 1
Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant
Jennifer Massey, Ian Sutton, D. F. David, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 72
Pulsed immune reconstitution therapy in multiple sclerosis
Per Soelberg Sørensen, Finn Sellebjerg
Therapeutic Advances in Neurological Disorders (2019) Vol. 12
Open Access | Times Cited: 70
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
Sibyl Wray, Eva Havrdová, David R. Snydman, et al.
Multiple Sclerosis Journal (2018) Vol. 25, Iss. 12, pp. 1605-1617
Open Access | Times Cited: 69
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
Virginia Devonshire, Richard Odame Phillips, Hilary Wass, et al.
Journal of Neurology (2018) Vol. 265, Iss. 11, pp. 2494-2505
Open Access | Times Cited: 63
Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
Silvia Medina, Noelia Villarrubia, Susana Sainz de la Maza, et al.
Multiple Sclerosis Journal (2017) Vol. 24, Iss. 10, pp. 1317-1327
Closed Access | Times Cited: 53
Alemtuzumab for Multiple Sclerosis
Mark Willis, Neil P. Robertson
Current Neurology and Neuroscience Reports (2016) Vol. 16, Iss. 9
Open Access | Times Cited: 49
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
Wendy Gilmore, Brett T. Lund, Peili Li, et al.
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 46
Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review
Johann Sellner, Paulus Rommer
Autoimmunity Reviews (2020) Vol. 19, Iss. 4, pp. 102492-102492
Closed Access | Times Cited: 43
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
Brian Steingo, Yaser Al Malik, Ann Bass, et al.
Journal of Neurology (2020) Vol. 267, Iss. 11, pp. 3343-3353
Open Access | Times Cited: 43
CD4+ T-Cell Senescence in Neurodegenerative Disease: Pathogenesis and Potential Therapeutic Targets
Yan Gao, Yaoping Lu, Xiaojing Liang, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 749-749
Open Access | Times Cited: 5
Drugs approved for the treatment of multiple sclerosis: review of their safety profile
Fabiana Auricchio, Cristina Scavone, Daniela Cimmaruta, et al.
Expert Opinion on Drug Safety (2017) Vol. 16, Iss. 12, pp. 1359-1371
Closed Access | Times Cited: 45
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
Georgios K. Vasileiadis, Efthimios Dardiotis, Αthanasios Mavropoulos, et al.
Autoimmunity Highlights (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 43
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
Heinz Wiendl, Matthew Carraro, Cristoforo Comi, et al.
Neurology Neuroimmunology & Neuroinflammation (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 40
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
Yahiya Y. Syed
Drugs (2020) Vol. 81, Iss. 1, pp. 157-168
Closed Access | Times Cited: 34
Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
Isabella Laura Simone, Carla Tortorella, Alma Ghirelli
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 29
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
Richard G. Phelps, Jonathan Winston, Daniel Wynn, et al.
Multiple Sclerosis Journal (2019) Vol. 25, Iss. 9, pp. 1273-1288
Open Access | Times Cited: 31
The Dichotomous Role of Inflammation in the CNS: A Mitochondrial Point of View
Bianca Vezzani, Marianna Carinci, Simone Patergnani, et al.
Biomolecules (2020) Vol. 10, Iss. 10, pp. 1437-1437
Open Access | Times Cited: 31
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years
Jiwon Oh, Anat Achiron, Elisabeth Gulowsen Celius, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 43, pp. 102146-102146
Open Access | Times Cited: 29
Alemtuzumab for the treatment of multiple sclerosis
Jennifer R. Evan, Subutay Berke Bozkurt, Nikita Thomas, et al.
Expert Opinion on Biological Therapy (2018) Vol. 18, Iss. 3, pp. 323-334
Closed Access | Times Cited: 31
Page 1 - Next Page

Scroll to top